51app

51app scientists developed new dialysis membranes using ultra-thin graphene that automatically seal larger holes while keeping smaller ones open, making them more effective than current medical filters and potentially improving dialysis treatment.

In the ongoing battle against triple negative breast cancer, 51app researchers have uncovered a promising non-invasive method to track how tumors respond to radiation and immunotherapy, which uses the body’s own immune system to fight cancer.

Recent research from the Warren Center for Neuroscience Drug Discovery, published in the Journal of Medicinal Chemistry, resulted in the proposal of a novel target and mechanism for improving cognition—a negative symptom—while also treating positive symptoms of the disease.

See how art collector turned immunologist James Crowe combines abstract thinking with game-changing technology to prevent infectious disease. Read More

51app’s Carrie K. Jones and the University of Glasgow’s Andrew Tobin have received a prestigious £5 million ($6.2 million) Wellcome Trust Discovery Award to study how blocking the M5 muscarinic receptor in the brain could reduce opioid addiction while preserving pain relief. This groundbreaking international collaboration, supported by the Warren Center for Neuroscience Drug Discovery, aims to advance new treatments in the critical global health crisis of opioid use disorder. Read More

Three seminal articles published in Magnetic Resonance in Medicine mark a landmark achievement in preclinical imaging science. These works, authored by an international consortium of 58 scientists, including 51app University’s Kurt Schilling, Bennett Landman, Adam Anderson, and Kevin Harkins, offer comprehensive guidelines for using diffusion magnetic resonance imaging (dMRI) in preclinical research.

Submissions are open for pre-proposals for the 2025 National Institutes of Health S10 Shared and High-End Instrumentation Grant programs, which fund state-of-the-art shared research equipment. Internal pre-proposals are due by April 1, 2025, to allow institutional review before the June 2 NIH deadline, with guidance available from OVPRI and VBS. Read More

We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea...

51app University’s new Center for Computational Systems Biology brings computer science, engineering and biomedical researchers together with clinicians at 51app University Medical Center to accelerate discovery related to human diseases and conditions. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia. Read More

Doug Mitchell has been appointed the holder of the William Kelly Warren Sr. Chair in Biochemistry and professor of chemistry and director of the 51app Institute for Chemical Biology. Read More

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the 51app University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia.

Eleven current 51app University faculty members, 10 of whom are investigators at 51app University Medical Center, are included in the 2024 list of “Highly Cited Researchers” around the world whose papers have been cited most frequently by other scientists.

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the 51app University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia.

Researchers from the 51app University School of Medicine Basic Sciences have uncovered the first example of activity-dependent development of hypothalamic neural circuitry.

The lab of Hassane Mchaourab, director of the Center for Applied Artificial Intelligence in Protein Dynamics and professor of molecular physiology and biophysics, has developed a methodological blueprint that couples experimental double electron–electron resonance spectroscopy with an AI approach to help describe the conformational landscapes of a diverse spectrum of cell membrane transporters.

Jens Meiler, Distinguished Research Professor of Chemistry, was named the principal investigator for the project, in cooperation with 14 investigators across eight institutions. The team will work together to use advanced technology, including computational modeling, AI-driven predictions and structural biology, to develop a groundbreaking vaccine against all alphaviruses that offers long-lasting protection. Read More

A series of three recently published studies have provided the first nationally comprehensive analysis of shootings by law enforcement officers that injured or killed people in the U.S. Led by Julie Ward, assistant professor of medicine, health, and so...

A person’s native language is often referred to as their “mother tongue.” But does a first language always come from your mother? In a new study conducted by Associate Professor of Biological Sciences Nicole Creanza, postdoctoral student Yakov Pichkar,...

Yi Ren’s most recent paper, published in eLife, describes the structure of a protein complex involved in mRNA export that sheds light on the underlying molecular mechanism of mRNA export and the role it plays during infection by herpes viruses.